• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

毫安诱导的SIAH1抑制通过调节CPSF1促进雄激素受体变体7的可变剪接。

mA-induced repression of SIAH1 facilitates alternative splicing of androgen receptor variant 7 by regulating CPSF1.

作者信息

Xia Lei, Han Qing, Duan Xuehui, Zhu Yinjie, Pan Jiahua, Dong Baijun, Xia Weiliang, Xue Wei, Sha Jianjun

机构信息

Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200001, People's Republic of China.

School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200001, People's Republic of China.

出版信息

Mol Ther Nucleic Acids. 2022 Mar 15;28:219-230. doi: 10.1016/j.omtn.2022.03.008. eCollection 2022 Jun 14.

DOI:10.1016/j.omtn.2022.03.008
PMID:35402071
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8965770/
Abstract

Androgen receptor splice variant 7 (AR-v7), a constitutively active transcription factor, plays a crucial role in the progression of castration-resistant prostate cancer (CRPC). Here, we found that the cleavage and polyadenylation specificity factor 1 (CPSF1) (the largest subunit of the multi-protein cleavage and polyadenylation specificity complex), regulated by the E3 ubiquitin ligases SIAH1, promoted AR-v7 expression. The data from microarray-based analysis and clinical specimen-based analysis showed that SIAH1 expression was decreased in PCa and was negatively correlated with aggressive phenotypes of PCa. SIAH1 repressed PCa cell growth and invasion under castrate conditions. SIAH1 directly interacted with CPSF1 and promoted ubiquitination and degradation of CPSF1. CPSF1 expression was negatively correlated with SIAH1 expression, but positively with PCa progression. CPSF1 overexpression switched the AR splicing pattern and facilitated the generation of the oncogenic isoform (AR-v7) by binding to the AAUAAA polyadenylation signal contained in AR-cryptic exon CE3. Functionally, SIAH1 acted as a tumor suppressor in PCa pathogenesis by repressing CPSF1-mediated AR-v7 generation. Finally, we demonstrated that mA methylation was concerned with the repression of SIAH1 in PCa. Our results define SIAH1/CPSF1/AR-v7 axis as a regulatory factor of PCa progression, providing a promising target for treating PCa.

摘要

雄激素受体剪接变体7(AR-v7)是一种组成型活性转录因子,在去势抵抗性前列腺癌(CRPC)的进展中起关键作用。在此,我们发现由E3泛素连接酶SIAH1调控的切割和聚腺苷酸化特异性因子1(CPSF1)(多蛋白切割和聚腺苷酸化特异性复合物的最大亚基)促进了AR-v7的表达。基于微阵列分析和基于临床标本分析的数据表明,SIAH1在前列腺癌中的表达降低,并且与前列腺癌的侵袭性表型呈负相关。在去势条件下,SIAH1抑制前列腺癌细胞的生长和侵袭。SIAH1直接与CPSF1相互作用,并促进CPSF1的泛素化和降解。CPSF1的表达与SIAH1的表达呈负相关,但与前列腺癌进展呈正相关。CPSF1的过表达改变了AR剪接模式,并通过与AR隐蔽外显子CE3中包含的AAUAAA聚腺苷酸化信号结合促进了致癌异构体(AR-v7)的产生。在功能上,SIAH1通过抑制CPSF1介导的AR-v7产生,在前列腺癌发病机制中发挥肿瘤抑制作用。最后,我们证明了甲基化与前列腺癌中SIAH1的抑制有关。我们的结果将SIAH1/CPSF1/AR-v7轴定义为前列腺癌进展的调节因子,为治疗前列腺癌提供了一个有前景的靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/553a8fcbd779/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/584b09255dc4/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/b520f0090981/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/b0da0d1b0955/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/16d321a92f90/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/7ff312794b86/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/7ad951516d44/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/8bd32befde39/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/553a8fcbd779/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/584b09255dc4/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/b520f0090981/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/b0da0d1b0955/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/16d321a92f90/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/7ff312794b86/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/7ad951516d44/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/8bd32befde39/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c3/8965770/553a8fcbd779/gr7.jpg

相似文献

1
mA-induced repression of SIAH1 facilitates alternative splicing of androgen receptor variant 7 by regulating CPSF1.毫安诱导的SIAH1抑制通过调节CPSF1促进雄激素受体变体7的可变剪接。
Mol Ther Nucleic Acids. 2022 Mar 15;28:219-230. doi: 10.1016/j.omtn.2022.03.008. eCollection 2022 Jun 14.
2
Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.激素敏感性前列腺癌和去势抵抗性前列腺癌中雄激素受体变异体7和泛素结合酶2C的转录水平
Prostate. 2017 Jan;77(1):60-71. doi: 10.1002/pros.23248. Epub 2016 Aug 22.
3
Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 to Suppress Enzalutamide-resistant Prostate Cancer Progression.使用 Malat1 小干扰 RNA 或雄激素受体剪接变体 7 降解增强剂 ASC-J9 进行临床前研究以抑制恩杂鲁胺耐药前列腺癌的进展。
Eur Urol. 2017 Nov;72(5):835-844. doi: 10.1016/j.eururo.2017.04.005. Epub 2017 May 18.
4
Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.雄激素受体及其剪接变体AR-V7在LNCaP前列腺癌细胞中对FOXA1敏感基因有不同的调控作用。
Int J Biochem Cell Biol. 2014 Sep;54:49-59. doi: 10.1016/j.biocel.2014.06.013. Epub 2014 Jul 4.
5
Restoration of FKBP51 protein promotes the progression of castration resistant prostate cancer.FKBP51蛋白的恢复促进去势抵抗性前列腺癌的进展。
Ann Transl Med. 2019 Dec;7(23):729. doi: 10.21037/atm.2019.11.127.
6
Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer.去势抵抗性前列腺癌中雄激素受体剪接变体7与雄激素受体表达水平的比值。
Oncol Lett. 2021 Dec;22(6):831. doi: 10.3892/ol.2021.13092. Epub 2021 Oct 13.
7
DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7.DBC1 通过正向调控 AR-V7 的 DNA 结合和稳定性促进去势抵抗性前列腺癌。
Oncogene. 2018 Mar;37(10):1326-1339. doi: 10.1038/s41388-017-0047-5. Epub 2017 Dec 18.
8
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.雄激素受体剪接变异体-7 的表达随着前列腺癌的去势抵抗而出现。
J Clin Invest. 2019 Jan 2;129(1):192-208. doi: 10.1172/JCI122819. Epub 2018 Nov 26.
9
Molecular Origin, Expression Regulation, and Biological Function of Androgen Receptor Splicing Variant 7 in Prostate Cancer.雄激素受体剪接变体 7 在前列腺癌中的分子起源、表达调控及生物学功能。
Urol Int. 2021;105(5-6):337-353. doi: 10.1159/000510124. Epub 2020 Sep 21.
10
Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.雄激素受体剪接变异体 7 在下一代雄激素受体信号抑制治疗去势抵抗性前列腺癌中的预后价值:系统评价和荟萃分析。
Eur Urol Focus. 2018 Jul;4(4):529-539. doi: 10.1016/j.euf.2017.01.004. Epub 2017 Jan 23.

引用本文的文献

1
Insulin-Like Growth Factor 2 mRNA-Binding Protein 2 (IGF2BP2) Promotes Castration-Resistant Prostate Cancer Progression by Regulating AR-V7 mRNA Stability.胰岛素样生长因子2信使核糖核酸结合蛋白2(IGF2BP2)通过调节AR-V7信使核糖核酸稳定性促进去势抵抗性前列腺癌进展。
Cancer Rep (Hoboken). 2025 Feb;8(2):e70096. doi: 10.1002/cnr2.70096.
2
The mA regulators in prostate cancer: molecular basis and clinical perspective.前列腺癌中的毫安调节器:分子基础与临床前景
Front Pharmacol. 2024 Aug 29;15:1448872. doi: 10.3389/fphar.2024.1448872. eCollection 2024.
3
Modulation of diverse biological processes by CPSF, the master regulator of mRNA 3' ends.

本文引用的文献

1
Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer.去势抵抗性前列腺癌中AR/AR-V7共同靶向及AR-V7特异性靶向的AR-V7下游基因的鉴定。
Transl Oncol. 2021 Jan;14(1):100915. doi: 10.1016/j.tranon.2020.100915. Epub 2020 Oct 20.
2
The RNA fold interactome of evolutionary conserved RNA structures in S. cerevisiae.酿酒酵母中进化保守 RNA 结构的 RNA 折叠相互作用组。
Nat Commun. 2020 Jun 3;11(1):2789. doi: 10.1038/s41467-020-16555-4.
3
Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation.
CPSF 对多种生物过程的调节作用,CPSF 是 mRNA 3' 端的主要调节因子。
RNA. 2024 Aug 16;30(9):1122-1140. doi: 10.1261/rna.080108.124.
4
The functions and mechanisms of RNA modification in prostate: Current status and future perspectives.前列腺中RNA修饰的功能与机制:现状与未来展望
Front Genet. 2024 May 10;15:1380746. doi: 10.3389/fgene.2024.1380746. eCollection 2024.
5
RNA N6-methyladenosine-modified-binding protein YTHDF1 promotes prostate cancer progression by regulating androgen function-related gene TRIM68.RNA N6-甲基腺苷修饰结合蛋白 YTHDF1 通过调节雄激素功能相关基因 TRIM68 促进前列腺癌的进展。
Eur J Med Res. 2023 Dec 2;28(1):552. doi: 10.1186/s40001-023-01533-5.
6
Proteomics analysis of carotid body tumor revealed potential mechanisms and molecular differences among Shamblin classifications.颈动脉体瘤的蛋白质组学分析揭示了 Shamblin 分类之间的潜在机制和分子差异。
Exp Biol Med (Maywood). 2023 Oct;248(20):1785-1798. doi: 10.1177/15353702231199475. Epub 2023 Oct 16.
7
RNA modification writers pattern in relation to tumor microenvironment and prognosis in prostate cancer.前列腺癌中RNA修饰写入蛋白模式与肿瘤微环境及预后的关系
Front Genet. 2023 Jan 18;13:1065424. doi: 10.3389/fgene.2022.1065424. eCollection 2022.
8
Research progress of mA methylation in prostate cancer.前列腺癌中 mA 甲基化的研究进展。
Asian J Androl. 2023 Mar-Apr;25(2):166-170. doi: 10.4103/aja202265.
9
Stem Cells as Target for Prostate cancer Therapy: Opportunities and Challenges.干细胞作为前列腺癌治疗的靶点:机遇与挑战。
Stem Cell Rev Rep. 2022 Dec;18(8):2833-2851. doi: 10.1007/s12015-022-10437-6. Epub 2022 Aug 11.
组蛋白赖氨酸去甲基化酶 KDM4B 调控雄激素受体的可变剪接以响应雄激素剥夺。
Nucleic Acids Res. 2019 Dec 16;47(22):11623-11636. doi: 10.1093/nar/gkz1004.
4
Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.阿帕鲁胺:用于治疗非转移性去势抵抗性前列腺癌的药物。
Drugs. 2019 Sep;79(14):1591-1598. doi: 10.1007/s40265-019-01194-x.
5
SIAH1 ubiquitin ligase mediates ubiquitination and degradation of Akt3 in neural development.SIAH1 泛素连接酶介导 Akt3 的泛素化和降解在神经发育中。
J Biol Chem. 2019 Oct 18;294(42):15435-15445. doi: 10.1074/jbc.RA119.009618. Epub 2019 Aug 30.
6
SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression.SF3B2 介导的 RNA 剪接驱动人类前列腺癌进展。
Cancer Res. 2019 Oct 15;79(20):5204-5217. doi: 10.1158/0008-5472.CAN-18-3965. Epub 2019 Aug 20.
7
Cancer treatment and survivorship statistics, 2019.2019 年癌症治疗与生存统计
CA Cancer J Clin. 2019 Sep;69(5):363-385. doi: 10.3322/caac.21565. Epub 2019 Jun 11.
8
Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells.鉴定和表征黑色素瘤和前列腺癌细胞中泛素连接酶 Siah1/2 的小分子抑制剂。
Cancer Lett. 2019 May 1;449:145-162. doi: 10.1016/j.canlet.2019.02.012. Epub 2019 Feb 14.
9
Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions.恩杂鲁胺耐药性去势抵抗性前列腺癌:挑战与解决方案
Onco Targets Ther. 2018 Oct 24;11:7353-7368. doi: 10.2147/OTT.S153764. eCollection 2018.
10
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.雄激素受体剪接变异体-7 的表达随着前列腺癌的去势抵抗而出现。
J Clin Invest. 2019 Jan 2;129(1):192-208. doi: 10.1172/JCI122819. Epub 2018 Nov 26.